![]() Two review authors screened searches and independently extracted details on risk of bias and numerical data. Primary outcomes were exacerbations requiring oral corticosteroids (OCS), validated measures of asthma control, and serious adverse events (including mortality). We included studies reported as full text, those published as abstract only, and unpublished data. ![]() Studies met the inclusion criteria if they compared LAMA as an add-on to LABA/ICS versus LABA/ICS alone for adults with asthma. We included parallel randomised controlled trials (RCTs) of at least 12 weeks' duration. We also searched, the WHO trials portal, and reference lists of other reviews, and we contacted trial authors for additional information. We identified trials from the Cochrane Airways Review Group Specialised Register (CAGR) up to January 2016. To assess the effects of adding a long-acting muscarinic antagonist (LAMA) to combination long-acting beta2-agonists (LABA) and inhaled corticosteroids (ICS) in adults whose asthma is not well controlled by LABA/ICS. Long-acting muscarinic antagonists (LAMA) are a class of inhaled drug which have been effective for people with chronic obstructive pulmonary disease and are now becoming available for people with asthma to take alongside their LABA/ICS inhaler. Please note, the advice provided is not a substitute for asking your health care professional about your specific situation.Maintenance treatment with long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) can relieve asthma symptoms and reduce the frequency of exacerbations, but there are limited treatment options for people who do not gain control on combination LABA/ICS. There are different combination inhalers (brand names are Advair, Breo, Dulera, and Symbicort) approved for treatment of asthma and/or COPDĭarlene – In answer to your question about safe inhalers for glaucoma, you may want to ask your eye doctor (ophthamologist) whether a muscarinic antagonist can be tried safely. The prescribing information for the muscarinic antagonist bronchodilators (brand names are Atrovent, Combivent, Incruse, Seebri, Spiriva, and Turdoza) states that these medications “should be used with caution in patients with narrow angle glaucoma.” A safe approach is for you to use a combination of a beta-agonist and inhaled corticosteroid. Closed angle is usually hereditary and affects those who are far-sighted (trouble seeing near). Open angle is the most common (90%) type and typically occurs after age 50. In a healthy eye, excess fluid leaves the eye through the drainage angle, keeping pressure stable. There are two major types of glaucoma – open angle and closed or narrow angle. You mentioned that you have “closed angle glaucoma.” As you know, glaucoma is an increase in pressure in the eye. Typically, “triple therapy” is used that includes an inhaled corticosteroid and both types of long-acting bronchodilators – beta-agonists and muscarinic antagonists. Use of one or more inhaled medications depends to a great extent on how severe are your symptoms and whether you have had frequent flare-ups. Inhalers are used to treat the inflammation of asthma and bronchodilators to open the breathing tubes for both asthma and emphysema. In general, those with both features of asthma and COPD have worse symptoms (cough and/of shortness of breath), poorer quality of life, and an increased risk of flare-ups (exacerbations) compared to those with COPD alone.įirst, it is important that you not smoke and avoid all irritants in the air, such as dust, fumes, particles, smog, etc. It is estimated that about 25% of those with COPD have features of asthma. Diagram shows overlap between asthma and COPD (chronic bronchitis and emphysema)
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |